



Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/528,377
Filing Date	January 4, 2006
First Named Inventor	Jeffrey S. Glenn
Group Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	STAN-316

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1					
	A2					
	A3					
	A4					
	A5					
	A6					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Country	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴ (if known)				
	B1						
	B2						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ROSENBERG, Recent advances in the molecular biology of Hepatitis C Virus, (2001), J. Mol. Biol., 313(3):451-64	
	C2	KATO, Molecular Biology of Hepatitis C Virus, (2001), Acta. Med. Okayama, Vol. 55. No. 3, pp.133-159	
	C3	PFISTER et al., Characterization of the Nucleoside Triphosphatase activity of Polio Virus Protein 2C reveals a mechanism by which guanidine inhibits Poliovirus replication, J. Biol. Chem., 274(11), 6992-7001, 1999	
	C4	UMEZU et al., Escherichia coli RecQ protein is a DNA helicase, PNAS 87:5363-5367, 1990	
	C5	TATE et al., Nucleotide specificity of Cardiac Sarcoplasmic Reticulum, J. Biol. Chem, 266, 24, 16165-16170, 1991	
	C6		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Examiner Signature	/Zachariah Lucas/	Date Considered	07/09/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 0231.